These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24080892)

  • 1. [Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].
    Picazo JJ; González-Romo F; García Rojas A; Peréz-Trallero E; Gil Gregorio P; de la Cámara R; Morató ML; Rodríguez A; Barberán J; Domínguez Hernández V; Linares Rufo M; Jimeno Sanz I; Portolés JM; Sanz Herrero F; Espinosa Arranz J; García-Sánchez V; Galindo Izquierdo M
    Rev Esp Quimioter; 2013 Sep; 26(3):232-52. PubMed ID: 24080892
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vaccination against pneumococcal infection in adults].
    Viejo JL
    Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():26-8. PubMed ID: 20084346
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
    Giglio N; Micone P; Gentile A
    Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunization and antimicrobials. Is there an association between the effects against Streptococcus pneumoniae?].
    Aguilar L; Giménez MJ
    Rev Esp Quimioter; 2007 Mar; 20(1):125-7. PubMed ID: 17530045
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pneumococcal infections: Appraisal and perspectives in terms of adult vaccination].
    Baratali L; Lang PO
    Presse Med; 2015 Nov; 44(11):1155-61. PubMed ID: 26363530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines: worth paying for the value returned.
    Grabenstein JD
    Ann Pharmacother; 2002 Sep; 36(9):1471-2. PubMed ID: 12229878
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Hjuler T; Kaltoft M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2008 Jul; 26(29-30):3765-71. PubMed ID: 18513840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance].
    Traut V
    Dtsch Med Wochenschr; 2008 May; 133(22):1207-8; author reply 1208. PubMed ID: 18491279
    [No Abstract]   [Full Text] [Related]  

  • 11. Pneumococcal vaccination of adults: polysaccharide or conjugate.
    Med Lett Drugs Ther; 2009 Jun; 51(1314):47-8. PubMed ID: 19528887
    [No Abstract]   [Full Text] [Related]  

  • 12. Pneumococcal infection in adults: burden of disease.
    Drijkoningen JJ; Rohde GG
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():45-51. PubMed ID: 24313448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal conjugate vaccines. A review.
    Galiza EP; Heath PT
    Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal vaccines in adults: assessing the evolving evidence.
    Grabenstein JD; Manoff SB
    Vaccine; 2011 Aug; 29(37):6149-54. PubMed ID: 21763386
    [No Abstract]   [Full Text] [Related]  

  • 17. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation.
    Ispahani P; Slack RC; Donald FE; Weston VC; Rutter N
    Arch Dis Child; 2004 Aug; 89(8):757-62. PubMed ID: 15269078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promises and challenges of pneumococcal conjugate vaccines for the developing world.
    Grijalva CG; Edwards KM
    Clin Infect Dis; 2006 Sep; 43(6):680-2. PubMed ID: 16912938
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotype replacement in perspective.
    Dagan R
    Vaccine; 2009 Aug; 27 Suppl 3():C22-4. PubMed ID: 19545935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease.
    Grau I; Ardanuy C; Liñares J; Podzamczer D; Schulze MH; Pallares R
    HIV Med; 2009 Sep; 10(8):488-95. PubMed ID: 19459987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.